Sanara MedTechSMTI
SMTI
About: Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.
Employees: 141
0
Funds holding %
of 7,430 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
0.7% more ownership
Funds ownership: 10.3% [Q1] → 11.0% (+0.7%) [Q2]
0% more funds holding
Funds holding: 49 [Q1] → 49 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
2% less capital invested
Capital invested by funds: $28.3M [Q1] → $27.7M (-$531K) [Q2]
16% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 19
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$54
64%
upside
Avg. target
$54
64%
upside
High target
$54
64%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Yi Chen | 64%upside $54 | Buy Maintained | 18 Aug 2025 |
Financial journalist opinion
Based on 3 articles about SMTI published over the past 30 days
Neutral
Seeking Alpha
1 week ago
Sanara MedTech Inc. (SMTI) Q2 2025 Earnings Call Transcript
Sanara MedTech Inc. (NASDAQ:SMTI ) Q2 2025 Earnings Call August 13, 2025 8:00 AM ET Company Participants Elizabeth B. Taylor - Chief Financial Officer Ronald T.
Negative
Zacks Investment Research
1 week ago
Sanara MedTech Inc. (SMTI) Reports Q2 Loss, Tops Revenue Estimates
Sanara MedTech Inc. (SMTI) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to a loss of $0.41 per share a year ago.
Neutral
GlobeNewsWire
1 week ago
Sanara MedTech Inc. Reports Second Quarter 2025 Financial Results (Unaudited)
Net Revenue Increased 28% Year-Over-Year in Q2; Increased 27% Year-Over-Year in First Six Months of 2025 Announces Process to Evaluate Strategic Alternatives for its Tissue Health Plus, LLC Subsidiary FORT WORTH, TX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today reported its financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Summary ● Net revenue increased 28% to $25.8 million, compared to $20.2 million in the second quarter of 2024.
Neutral
GlobeNewsWire
1 month ago
Sanara MedTech to Report Second Quarter 2025 Financial Results on August 13, 2025
FORT WORTH, TX, July 15, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc . (“Sanara,” or the “Company”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today announced it will report its second quarter 2025 financial results on Wednesday, August 13, 2025 before the U.S. financial markets open.
Neutral
GlobeNewsWire
1 month ago
Sanara MedTech Inc. Announces Launch of Tissue Health Plus Wound Care Provider Pilot Program
Pilot program designed to provide real-world evidence in the use of Tissue Health Plus' technology platform FORT WORTH, TX, July 14, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today announced the recent launch, through its subsidiary, Tissue Health Plus, LLC (“THP”), of its wound care provider pilot program, a first of its kind, value-based wound care offering designed for payers and risk-bearing entities, as well as value-based primary care companies. “We are pleased to announce that, during the second quarter, THP launched a pilot program in partnership with a wound care provider group delivering at-home care for chronic wounds across six states,” said Sam Muppalla, President and CEO of THP.
Neutral
Seeking Alpha
2 months ago
Sanara MedTech: Pursuing Rapid Expansion While Debt Levels Climb
Sanara MedTech's surgical revenue grew 26% year-over-year in Q1, with a gross margin of 92%. Surgical adjusted EBITDA was $2.7 million in Q1, while THP correspondingly posted a loss of $2 million. High debt levels and elevated interest expenses are key risks, along with the uncertainty surrounding the commercialization of THP.
Neutral
Seeking Alpha
3 months ago
Sanara MedTech Inc. (SMTI) Q1 2025 Earnings Call Transcript
Sanara MedTech Inc. (NASDAQ:SMTI ) Q1 2025 Earnings Conference Call May 14, 2025 8:00 AM ET Company Participants Ron Nixon - Executive Chairman, Chief Executive Officer Seth Yon - President, Chief Commercial Officer Sam Muppalla - President, Chief Executive Officer of Tissue Health Plus Elizabeth Taylor - Chief Financial Officer Conference Call Participants Matt Park - Cantor Fitzgerald Operator Welcome to the Sanara MedTech First Quarter of 2025 Earnings Conference Call. Please note that this conference call is being recorded and a replay will be available on the Investor Relations page of the company's website shortly.
Negative
Zacks Investment Research
3 months ago
Sanara MedTech Inc. (SMTI) Reports Q1 Loss, Tops Revenue Estimates
Sanara MedTech Inc. (SMTI) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.21 per share a year ago.
Neutral
GlobeNewsWire
3 months ago
Sanara MedTech Inc. Reports First Quarter 2025 Financial Results (Unaudited)
Q1 Net Revenue Increased 26% Year-Over-Year FORT WORTH, TX, May 14, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, today reported its financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Summary ● Net revenue increased 26% to $23.4 million, compared to $18.5 million in the first quarter of 2024.
Neutral
GlobeNewsWire
4 months ago
Sanara MedTech to Report First Quarter 2025 Financial Results on May 14, 2025
FORT WORTH, TX, April 23, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc . (“Sanara,” or the “Company”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, today announced it will report its first quarter 2025 financial results on Wednesday, May 14, 2025 before the U.S. financial markets open.
Charts implemented using Lightweight Charts™